NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Bolt Biotherapeutics, Inc. (BOLT) Stock Analysis

Bolt Biotherapeutics, Inc. (BOLT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BOLT

$3.90

+$0.00 (+0.13%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BOLT with… →

BOLT Key Statistics

As of Sep 4, 2026
Trading
Open
$3.90
Previous Close
$3.90
Day's Range
3.85–4.00
52-Week Range
3.13–7.20
Volume
8.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.09
Valuation
Market Cap
$7.51M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.60
EPS (ttm)Profit attributable to each share over the last twelve months.
−16.51
Financials (FY)
Revenue (FY)
$7.70M+0.07%
Net Income (FY)
−$33.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.93M
1-Year Return
−19.42%
Dividend and dates
Avg Volume
24.33K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BOLT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.68%
2025−48.90%
2024−52.23%
2023−13.85%
2022−73.47%
2021 (partial year)−84.76%

As of September 4, 2026.

BOLT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.70M−$33.38M−433.7%
2024$7.69M−$63.12M−820.8%
2023$7.88M−$69.20M−878.6%
2022$5.73M−$88.10M−1537.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.70M—−$34.63M−$33.38M−433.7%
2024$7.69M—−$68.24M−$63.12M−820.8%
2023$7.88M—−$76.20M−$69.20M−878.6%
2022$5.73M—−$90.32M−$88.10M−1537.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BOLT Valuation vs Biotechnology Median

Median of 656 stocks
MetricBOLTBiotechnology medianvs median
P/S ratio1.6015.260.1x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bolt Biotherapeutics, Inc. (BOLT) is capitalised at $7.51M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 23 employees.

The 52-week range on file runs from $3.13 to $7.20. BOLT last closed at $3.90 on September 4, 2026. That is $0.00 (+0.13%) against the previous close. The latest close sits 24.6% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $7.70M. Against the prior fiscal year total of $7.69M, that is a change of +0.07%. The same year closed with a net loss of $33.38M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −16.51.

Across the 4 fiscal years on file, revenue moves from $5.73M in 2022 to $7.70M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1.6 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.09. Annualized volatility over the trailing 5 years is 74.24%. The trailing one-year price return is −19.42%. Across 5 years the annualized return works out at −59.81%.

Growth & Income

The record shows no dividend for BOLT.

Across the complete calendar years on file, 2023 returned −13.85% and 2022 returned −73.47%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −28.68% year to date.

Peer Comparison

Bolt Biotherapeutics, Inc. (BOLT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bolt Biotherapeutics, Inc. BOLT $7.51M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Bolt Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Visit website →